CMG Pharmaceutical Co., Ltd. (058820.KQ)
KRW 2470.0
(0.2%)
KRW 2470.0
(0.2%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 6.45 Billion KRW | 1763.15% |
| 2022 | -388.13 Million KRW | -112.26% |
| 2021 | 3.16 Billion KRW | 1372.34% |
| 2020 | 214.99 Million KRW | -91.86% |
| 2019 | 2.64 Billion KRW | 1395.87% |
| 2018 | 176.55 Million KRW | 0.17% |
| 2017 | 176.25 Million KRW | 668.39% |
| 2016 | 22.93 Million KRW | -95.18% |
| 2015 | 475.6 Million KRW | 6.79% |
| 2014 | 445.37 Million KRW | 36.02% |
| 2013 | 327.43 Million KRW | 17.78% |
| 2012 | 278 Million KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 5.98 Billion KRW | 166.97% |
| 2024 Q1 | 2.24 Billion KRW | 184.64% |
| 2023 Q2 | 3.69 Billion KRW | 37.22% |
| 2023 FY | 6.45 Billion KRW | 1763.15% |
| 2023 Q4 | -2.64 Billion KRW | -197.77% |
| 2023 Q1 | 2.69 Billion KRW | 153.4% |
| 2023 Q3 | 2.7 Billion KRW | -26.79% |
| 2022 Q3 | 257.13 Million KRW | -1.08% |
| 2022 FY | -388.13 Million USD | -112.26% |
| 2022 Q4 | -5.04 Billion KRW | -2063.28% |
| 2022 Q2 | 259.94 Million KRW | 64.21% |
| 2022 Q1 | 158.29 Million KRW | 18.59% |
| 2021 Q1 | 127.1 Million KRW | -33.44% |
| 2021 FY | 3.16 Billion USD | 1372.34% |
| 2021 Q2 | 187.97 Million KRW | 47.89% |
| 2021 Q3 | 204.43 Million KRW | 8.76% |
| 2021 Q4 | 133.47 Million KRW | -34.71% |
| 2020 Q3 | 80.24 Million KRW | 881.58% |
| 2020 Q1 | 76.38 Million KRW | 5.48% |
| 2020 Q2 | 8.17 Million KRW | -89.3% |
| 2020 FY | 214.99 Million USD | -91.86% |
| 2020 Q4 | 190.95 Million KRW | 137.97% |
| 2019 Q2 | 91.02 Million KRW | 3.29% |
| 2019 Q4 | 72.41 Million KRW | -26.54% |
| 2019 Q1 | 88.13 Million KRW | 175.25% |
| 2019 Q3 | 98.58 Million KRW | 8.3% |
| 2019 FY | 2.64 Billion USD | 1395.87% |
| 2018 FY | 176.55 Million USD | 0.17% |
| 2018 Q4 | 32.01 Million KRW | -16.19% |
| 2018 Q3 | 38.2 Million KRW | -18.51% |
| 2018 Q2 | 46.88 Million KRW | -21.13% |
| 2018 Q1 | 59.44 Million KRW | 35.74% |
| 2017 Q1 | 46.12 Million KRW | 188.7% |
| 2017 Q2 | 66.73 Million KRW | 44.69% |
| 2017 Q3 | 19.61 Million KRW | -70.61% |
| 2017 FY | 176.25 Million USD | 668.39% |
| 2017 Q4 | 43.79 Million KRW | 123.32% |
| 2016 FY | 22.93 Million USD | -95.18% |
| 2016 Q4 | 15.97 Million KRW | 104.83% |
| 2016 Q3 | 7.79 Million KRW | -69.53% |
| 2016 Q2 | 25.59 Million KRW | 196.84% |
| 2016 Q1 | -26.43 Million KRW | -138.94% |
| 2015 Q2 | 140.2 Million KRW | 14.32% |
| 2015 Q1 | 122.64 Million KRW | 1.16% |
| 2015 FY | 475.6 Million USD | 6.79% |
| 2015 Q4 | 67.87 Million KRW | -53.15% |
| 2015 Q3 | 144.88 Million KRW | 3.34% |
| 2014 Q4 | 121.23 Million KRW | -7.31% |
| 2014 Q3 | 130.8 Million KRW | 18.62% |
| 2014 Q2 | 110.27 Million KRW | 32.75% |
| 2014 Q1 | 83.06 Million KRW | 4.33% |
| 2014 FY | 445.37 Million USD | 36.02% |
| 2013 Q1 | 76.58 Million KRW | 24.83% |
| 2013 FY | 327.43 Million USD | 17.78% |
| 2013 Q3 | 83.37 Million KRW | -5.09% |
| 2013 Q2 | 87.85 Million KRW | 14.71% |
| 2013 Q4 | 79.62 Million KRW | -4.51% |
| 2012 Q4 | 61.35 Million KRW | 0.0% |
| 2012 FY | 278 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -19.42 Billion KRW | 133.228% |
| Celltrion Pharm, Inc. | 21.26 Billion KRW | 69.643% |
| Huons Global Co., Ltd. | 38.38 Billion KRW | 83.182% |
| DongKook Pharmaceutical Co., Ltd. | 47.17 Billion KRW | 86.316% |
| Enzychem Lifesciences Corporation | -9.32 Billion KRW | 169.216% |
| Humedix Co., Ltd. | 24.82 Billion KRW | 73.992% |
| Boditech Med Inc. | 25.94 Billion KRW | 75.121% |
| EuBiologics Co., Ltd. | -13.87 Billion KRW | 146.512% |
| FutureChem Co.,Ltd | -6.7 Billion KRW | 196.22% |
| Huons Co., Ltd. | 50.47 Billion KRW | 87.21% |
| BNC Korea Co., Ltd. | 25.68 Billion KRW | 74.868% |
| AptaBio Therapeutics Inc. | -12.06 Billion KRW | 153.52% |